NICE Rates Choongwae's Bond as BB+

Published: 2001-08-06 06:56:00

Updated: 2001-08-06 06:56:00

The National Information & Credit Evaluation Inc. has given a credit rating of BB+ to the corporate bonds of Choongwae Pharma Corp. BB+ in its 36th main evaluation released on July 28.

Prior to this, Choongwae's credit rating was 'BB+' in the 34th regular evaluation for the corporate bonds o...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK